中生製藥(01177.HK)腦神經保護劑注射液獲批新增適應症用於漸凍症

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

中生製藥(01177.HK)腦神經保護劑注射液獲批新增適應症用於漸凍症

阿思達克 05-27 16:35

中國生物製藥(01177.HK)公布，集團研發的腦神經保護劑「依達拉奉氯化鈉注射液」(商品名稱：依必坦；規格：100ml)，繼早前國內首仿獲批上市後，剛獲得中國國家藥品監督管理局頒發藥品補充申請批件，批准新增適應症，用於抑制肌萎縮側索硬化症(俗稱「漸凍症」，ALS)的功能障礙進展。依必坦成為國內唯一同時擁有腦梗塞和ALS兩大適應症的依達拉奉製劑。

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

中生製藥(01177.HK)腦神經保護劑注射液獲批新增適應症用於漸凍症

Services

About Us

Agreement Statement